Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CRISPR/Cas9 gene editing in induced pluripotent stem cells to investigate the feline hypertrophic cardiomyopathy causing MYBPC3/R820W mutation.

PloS one - 1 Jan 2024

Dutton Luke C, Dudhia Jayesh, Guest Deborah J, Connolly David J

Abstract excerpt

Hypertrophic cardiomyopathy (HCM) is the most common heart disease in domestic cats, often leading to congestive heart failure and death, with current treatment strategies unable to reverse or prevent progression of the disease. The underlying pathological processes driving HCM remain unclear, which hinders novel drug discovery. The aim of this study was to generate a cellular model of the feline HCM-causing...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cardiomyopathy, Hypertrophic
Share to Carrier Proteins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cat Diseases

Share to CRISPR-Cas Systems

Share to Gene Editing

Share to Induced Pluripotent Stem Cells

Share to Myocytes, Cardiac

Source

Open in PubMed Open full text

Identifiers

PMID: 39388496
DOI: 10.1371/journal.pone.0311761
PMCID: PMC11466433

Genes

MYBPC3

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CRISPR/Cas9 gene editing in induced pluripotent stem cells to investigate the feline hypertrophic cardiomyopathy causing MYBPC3/R820W mutation.PMID 39388496Read ↗

MYBPC3-c.772G>A mutation results in haploinsufficiency and altered myosin cycling kinetics in a patient induced stem cell derived cardiomyocyte model of hypertrophic cardiomyopathy.Semantic proximity Read ↗

cMyBP-C ablation in human engineered cardiac tissue causes progressive Ca2+-handling abnormalities.Semantic proximity Read ↗

Generation of two heterozygous MYBPC3 mutation-carrying human iPSC lines, SCVIi001-A and SCVIi002-A, for modeling hypertrophic cardiomyopathy.Semantic proximity Read ↗

CRISPR/Cas9 editing in human pluripotent stem cell-cardiomyocytes highlights arrhythmias, hypocontractility, and energy depletion as potential therapeutic targets for hypertrophic cardiomyopathySemantic proximity Read ↗

Single Cell Transcriptomic Profiling of MYBPC3-Associated Hypertrophic Cardiomyopathy Across Species Reveals Conservation of Biological Process But Not Gene Expression.Semantic proximity Read ↗

MYBPC3 deficiency in cardiac fibroblasts drives their activation and contributes to fibrosisSemantic proximity Read ↗

<i>MYBPC3</i> D389V Variant Induces Hypercontractility in Cardiac OrganoidsSemantic proximity Read ↗

MLP-deficient human pluripotent stem cell derived cardiomyocytes develop hypertrophic cardiomyopathy and heart failure phenotypes due to abnormal calcium handlingSemantic proximity Read ↗

Homology-directed repair of an MYBPC3 gene mutation in a rat model of hypertrophic cardiomyopathy.Semantic proximity Read ↗

iPSC-Based Modeling of Variable Clinical Presentation in Hypertrophic Cardiomyopathy.Semantic proximity Read ↗

MYBPC3 deficiency in cardiac fibroblasts drives their activation and contributes to fibrosis.Semantic proximity Read ↗

Modeling hypertrophic cardiomyopathy with human cardiomyocytes derived from induced pluripotent stem cellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.